MAY 26·finanznachrichten.de▲
Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented new clinical data on plozasiran at the 94th European Atherosclerosis Society Congress in Athens. The company said a single 25 mg dose showed similar pharmacodynamic responses (APOC3 and triglyceride reductions) in patients with moderate-to-severe renal or moderate hepatic impairment, with no new safety signals and no dose adjustment needed. It also reported a pregnancy case suggesting sustained fasting TG lowering after preconception exposure.
MAY 26·insidermonkey.com▲
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026
The article discusses AI-related predictions and promotes a newsletter tied to Arrowhead Pharmaceuticals (ARWR). It says Bernstein raised ARWR’s price target after a “solid start” to 2026, but provides no specific figures. The rest focuses on billionaire and consulting views on AI’s economic potential and advertises subscription offers, including claims of past stock returns.
